

PHARMACEUTICAL 2023

## Syndax Pharmaceuticals Inc Rank 42 of 446





Syndax 🌮



RealRate

PHARMACEUTICAL 2023



## Syndax Pharmaceuticals Inc Rank 42 of 446

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 205% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	489,786
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,065
Liabilities, Non-Current	722
Other Assets	7,430
Other Compr. Net Income	-851
Other Expenses	0
Other Liabilities	0
Other Net Income	2,419
Other Revenues	0
Property and Equipment	20
Research and Development	118,499
Selling, General and Administrative Expense	33,258

Output Variable	Value in 1000 USD
Assets	497,236
Liabilities	29,787
Expenses	151,757
Revenues	0
Stockholders Equity	467,449
Net Income	-149,338
Comprehensive Net Income	-149,764
Economic Capital Ratio	248%

